Mersana Therapeutics, Inc. (MRSN)

2.7300 +0.1500 (+5.81%) 收市：04:00PM EDT

Mersana Therapeutics, Inc.

840 Memorial Drive
Cambridge, MA 02139
United States
617 498 0020
https://www.mersana.com

版塊: Healthcare
行業: Biotechnology
全職員工: 123

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Martin H. Huber M.D.	President, CEO & Director	780.46k	無	1961
Mr. Brian C. DeSchuytner	Senior VP, CFO & COO	567.04k	無	1978
Dr. Timothy B. Lowinger Ph.D.	Senior VP and Chief Science & Technology Officer	587.53k	無	1964
Ms. Alejandra Veronica Carvajal J.D.	Senior VP, Secretary & Chief Legal Officer	558.12k	無	1974
Mr. Mohan Bala Ph.D.	Senior VP & Chief Development Officer	549.43k	無	1965
Mr. Mikhail Papisov Ph.D.	Co-Founder	無	無	無
Mr. Ashish Mandelia	Chief Accounting Officer	無	無	1975
Mr. Jason Fredette	Senior Vice President of Investor Relations & Corporate Communications	無	無	無
Mr. Chuck Miller	Senior Vice President of Regulatory Affairs	無	無	無
Mr. Marc Damelin	Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

公司管治

截至 2024年5月1日 止，Mersana Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：3；董事會：6；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。